Qiraat Azeem

Qiraat Azeem

Auto-generated profile, based on publicly available information

Qiraat Azeem

Internal Medicine Indiana University Health, Ball Memorial Hospital, Muncie, Indiana, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
SMSasmith Menakuru
Sasmith Menakuru
QAQiraat Azeem
Qiraat Azeem
APAdelina Priscu
Adelina Priscu
Ibrahim KhanIbrahim Khan
Ibrahim Khan
ABAmir Fathi Beirat
Amir Fathi Beirat
The authors report the first case of stage 4 cytokine release syndrome (CRS) (graded by the National Cancer Institute Common Terminology Criteria for Adverse Effects scale) involving a patient with advanced metastatic melanoma who was treated with the combination of two monoclonal antibodies, nivolumab (anti-programmed cell death receptor 1 inhibitor [PD-1]) and ipilimumab (a cytotoxic T lymphocyte-associated antigen 4 inhibitor [CTLA-4]) after her first dose of both. The patient was treated initially with methylprednisolone and tocilizumab but was refractory to treatment. A trial of etanercept was initiated due to her elevated levels of TNF-α which elicited a satisfactory response. Monoclonal antibody therapy is a new tool for the treatment of many cancers, and therefore there may be a subsequent rise in the cases of CRS and this case exemplifies a treatment algorithm. Utilizing levels of cytokines assists in tailoring treatment such as in this case where etanercept, a TNF-α inhibitor, was utilized due to the patient’s elevated levels of TNF-α.